PolarityTE (NSDQ:PTE) said last week that it registered its bone repair product, OsteoTE, with the FDA.
The Utah-based company’s technology is an autologous, homologous product designed to repair, reconstruct and replace bone using a patient’s own cells.
Get the full story at our sister site, Drug Delivery Business News.